רווח תפעולי לפני ניכוי פחת: Avalo Therapeutics (AVTX)

Avalo Therapeutics, Inc (AVTX) relies on external financing due to a lack of profitable products and negative cash flow. The EBITDA_Co trend reflects the asset's current resilience, with the current value standing at 0.00. The company's prospects are based on the creation of targeted antibodies to the LIGHT cytokine and the development of innovative cell-signaling blockade methods for the therapy of severe autoimmune skin and lung lesions.

Professional asset selection is based on comparing current operating profit with historical data to assess the rate of capital reproduction. By analyzing the underlying operating result before depreciation, an investor measures the actual cash flow from core operations, which serves as a critical viability indicator between equity offering stages for the speculative business of Avalo Therapeutics (AVTX) facing liquidity depletion risks.